<DOC>
	<DOCNO>NCT00028678</DOCNO>
	<brief_summary>RATIONALE : Dalteparin may stop growth cancer stop blood flow tumor block enzyme necessary tumor cell growth . Radiation therapy use high-energy x-rays damage tumor cell . Combining dalteparin radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine dalteparin radiation therapy treat patient newly diagnose supratentorial glioblastoma multiforme .</brief_summary>
	<brief_title>Dalteparin Radiation Therapy Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether dalteparin , initiated time conventional radiotherapy , improve median survival patient newly diagnose supratentorial glioblastoma multiforme . - Determine time progression patient treat regimen . - Determine incidence thromboembolic event patient treat regimen . - Determine feasibility toxicity dalteparin patient population . OUTLINE : This multicenter study . Patients undergo cranial irradiation 5 day week 7 week . Beginning concurrently initiation radiotherapy , patient receive dalteparin subcutaneously daily 2 year absence unacceptable toxicity . Patients may continue receive dalteparin year 2 discretion investigator . Patients follow every 3 month 2 year every 6 month 5 year study entry . PROJECTED ACCRUAL : A total 72 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm newly diagnose supratentorial glioblastoma multiforme At least 2 week 4 week since prior surgery Patients biopsy must least 1 week past surgery PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm^3 No history heparininduced thrombocytopenia No coagulopathy Hepatic : Bilirubin great 2.5 mg/dL AST great 3 time upper limit normal ( ULN ) PT/aPTT great 1.5 time ULN Renal : Creatinine great 2.0 mg/dL No gross hematuria within past 6 month Cardiovascular : No uncontrolled hypertension No unstable angina No symptomatic congestive heart failure No myocardial infarction within past 6 month No uncontrolled cardiac arrhythmia Gastrointestinal : No peptic ulcer disease within past 6 month Negative stool guaiac Negative endoscopy require positive stool guaiac Other : No known hypersensitivity dalteparin , heparin , pork product No CNS trauma within past 3 month No intracranial intraocular hemorrhage , unless relate surgery , within past 6 month No retinal detachment within past 6 month No concurrent malignancy receive treatment No active infection No AIDSrelated illness HIV negative Must weigh least 90 pound ( 40 kg ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunomodulators No concurrent investigational matrix metalloproteinase inhibitor antiangiogenesis agent Chemotherapy : Prior chemotherapy malignancy allow No concurrent standard investigational cytotoxic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior cranial irradiation Prior radiotherapy malignancy allow Concurrent radiotherapy allow Surgery : See Disease Characteristics Recovered prior surgery No prior eye ear surgery Other : No concurrent nonsteroidal antiinflammatory drug No ongoing concurrent aspirin anticoagulation therapy except routine central venous catheter flush No concurrent nonprotocol therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>